Price
$28.97+139%1Y
1M+4.0%1Y+139%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierValue97
Quality61
Momentum78
Growth-
What they do
We are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. Our initial focus is on developing our novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression, or TRD. Our portfolio currently includes GH001, our proprietary inhalable mebufotenin product candidate and GH002, our proprietary intravenous mebufotenin product candidate.
In the company’s own words · 20-F filed Mar 5, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$1.53B
1Y Return+139%
5Y Return+40%
Raw charts
6 series · TTMAs reported to the SEC, without any scoring.